Current Concepts in Pregnancy-Associated Hypertension: Diagnosis and Management

Abstract

Hypertensive disorders in pregnancy represent a significant cause of maternal and perinatal morbidity and mortality worldwide. This review synthesizes current evidence and clinical practice guidelines on the classification, epidemiology, pathophysiology, risk factors, clinical presentation, diagnosis, management, and emerging therapies in hypertensive disorders of pregnancy. Emphasizing recent advances and practical implications, the article aims to provide a comprehensive resource for clinicians and healthcare professionals involved in the care of pregnant patients.

Introduction

Hypertensive disorders in pregnancy (HDP) encompass a spectrum of conditions, including chronic hypertension, gestational hypertension, preeclampsia, eclampsia, and preeclampsia superimposed on chronic hypertension. These disorders affect approximately 5–10% of pregnancies globally and are among the leading contributors to adverse maternal and fetal outcomes. Given the substantial burden and evolving management strategies, it is imperative for clinicians to maintain up-to-date knowledge of the pathogenesis, clinical features, and evidence-based approaches to diagnosis and treatment of HDP.

Epidemiology / Disease Burden

The global burden of HDP is considerable, with prevalence rates varying by region, ethnicity, and access to antenatal care. In developed countries, preeclampsia complicates 2–5% of pregnancies, whereas rates can exceed 10% in certain low-resource settings. HDP contribute to 10–15% of maternal deaths worldwide, with preeclampsia and eclampsia accounting for the majority of these cases. The associated risks to the fetus include preterm birth, intrauterine growth restriction, placental abruption, and stillbirth. Long-term, women with a history of HDP face higher lifetime risks of cardiovascular and renal disease. The significant healthcare resource utilization and implications for both maternal and neonatal health underscore the need for vigilant screening and management.

Pathophysiology

The underlying mechanisms of HDP are complex and multifactorial. In preeclampsia, abnormal placentation during early gestation leads to impaired trophoblastic invasion of maternal spiral arteries, resulting in high-resistance placental vessels and reduced placental perfusion. This, in turn, triggers the release of antiangiogenic factors such as soluble fms-like tyrosine kinase-1 (sFlt-1) and endoglin, which disrupt endothelial function and promote systemic vasoconstriction, inflammation, and multiorgan dysfunction. Chronic hypertension and gestational hypertension involve distinct mechanisms, with the former reflecting pre-existing vascular pathology and the latter often attributed to maternal predisposition unmasked by pregnancy-related hemodynamic changes. Genetic, immunological, and environmental factors interplay in the pathogenesis, influencing both susceptibility and severity.

Risk Factors

Numerous maternal characteristics increase the risk of developing HDP. These include advanced maternal age, nulliparity, obesity, pre-existing hypertension, diabetes mellitus, chronic kidney disease, autoimmune disorders such as systemic lupus erythematosus and antiphospholipid syndrome, multiple gestation, and family history of preeclampsia. Assisted reproductive technologies and certain ethnic backgrounds (e.g., African or South Asian descent) are also associated with elevated risk. Recent evidence suggests that abnormal placental perfusion and maternal vascular maladaptation play crucial roles in high-risk populations, supporting the need for targeted surveillance in predisposed women.

Clinical Features

The clinical presentation of HDP varies by subtype and severity. Gestational hypertension is characterized by new-onset hypertension (≥140/90 mmHg) after 20 weeks’ gestation without proteinuria or end-organ dysfunction. Preeclampsia is defined by hypertension plus proteinuria (≥300 mg/24 hours) or, in its absence, evidence of systemic involvement such as thrombocytopenia, elevated liver enzymes, renal insufficiency, pulmonary edema, or neurological symptoms (e.g., headache, visual changes). Eclampsia refers to the occurrence of generalized tonic-clonic seizures in a woman with preeclampsia. Chronic hypertension is diagnosed when elevated blood pressure precedes pregnancy or is identified before 20 weeks’ gestation. Superimposed preeclampsia occurs when a woman with chronic hypertension develops new-onset proteinuria or organ dysfunction after 20 weeks. Symptoms may include headache, visual disturbances, right upper quadrant pain, and edema, but many cases are asymptomatic, highlighting the importance of routine antenatal screening.

Diagnosis

Diagnosis of HDP is based on clinical criteria, blood pressure measurement, and laboratory assessment. Accurate blood pressure monitoring, using validated devices and standardized technique, is essential. Proteinuria is typically confirmed with a 24-hour urine collection or spot protein-to-creatinine ratio. Laboratory evaluation includes assessment of renal and liver function, platelet count, and urinalysis. Additional studies, such as serum uric acid, lactate dehydrogenase, and coagulation profile, may aid in assessing disease severity. Doppler ultrasound of uterine arteries and biomarkers (e.g., sFlt-1/PlGF ratio) are emerging as adjuncts in risk stratification and prediction of adverse outcomes, although their use remains variable in clinical practice.

Treatment & Management

The cornerstone of management is timely recognition, risk stratification, and individualized care based on disease severity and gestational age. For gestational hypertension and preeclampsia without severe features, close monitoring and blood pressure control are central, with delivery recommended at 37 weeks or earlier if complications arise. Severe preeclampsia necessitates hospitalization, antihypertensive therapy (e.g., labetalol, nifedipine, hydralazine), and seizure prophylaxis with magnesium sulfate. Eclampsia is a medical emergency requiring immediate stabilization, seizure control, and expedited delivery. The only definitive cure for preeclampsia/eclampsia is delivery of the placenta. In chronic hypertension, optimization of antihypertensive medications preconceptionally and throughout pregnancy is critical; agents contraindicated in pregnancy (e.g., ACE inhibitors, ARBs) should be avoided. Multidisciplinary collaboration among obstetricians, maternal-fetal medicine specialists, and anesthesiologists is essential for optimal outcomes.

Recent Advances / Emerging Therapies

Research in HDP has focused on early prediction, prevention, and targeted therapies. Low-dose aspirin initiated before 16 weeks’ gestation has been shown to reduce the risk of preeclampsia in high-risk women. Calcium supplementation may benefit women with low dietary intake. Angiogenic biomarkers are being evaluated for their predictive value and may guide timing of delivery in severe cases. Novel therapeutic approaches, including statins and targeted immunomodulation, are under investigation but are not yet standard of care. Enhanced risk stratification using machine learning and integration of clinical and biomarker data holds promise for individualized management in the future.

Guideline Recommendations

International guidelines, including those from the American College of Obstetricians and Gynecologists (ACOG), the International Society for the Study of Hypertension in Pregnancy (ISSHP), and the National Institute for Health and Care Excellence (NICE), emphasize accurate diagnosis, risk-based surveillance, and prompt management of HDP. Key recommendations include routine antenatal blood pressure monitoring, use of aspirin prophylaxis in high-risk women, timely initiation of antihypertensive therapy, and magnesium sulfate for seizure prevention in severe preeclampsia and eclampsia. Delivery timing should balance maternal and fetal risks, with individualized decision-making based on gestational age, disease severity, and fetal status.

Conclusion

Hypertensive disorders in pregnancy are a major clinical challenge, requiring early recognition, multidisciplinary management, and evidence-driven interventions to optimize maternal and fetal outcomes. Advances in pathophysiological understanding and risk stratification have informed contemporary guidelines and led to improved prevention and therapeutic strategies. Ongoing research into novel biomarkers and targeted therapies offers hope for further reducing the burden of HDP. Continued vigilance, adherence to best practice recommendations, and individualized care remain paramount in reducing the global impact of these conditions.